| Description |
SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1].
|
| Related Catalog |
|
| Target |
SIRT1[1]
|
| In Vitro |
SRTCX1003 (0-10 μM; 24 h) 剂量依赖性降低 U2OS 细胞中乙酰化 p65 蛋白[1]。 SRTCX1003 (5 μM; 6 h) 减弱 HEK 293T/17 细胞中 TNFα 诱导的 p65 乙酰化[1]。 SRTCX1003 (0-100 μM; 2 h) 剂量依赖性减少 RAW 细胞中 LPS (HY-D1056) 诱导的 TNFα 分泌[1]。 Western Blot AnalysisHEK 293T/17 Cell Line: HEK 293T/17 Concentration: 5 μM Incubation Time: 6 h followed by 20 minutes TNFα stimulation Result: Significantly reduced TNFα-stimulated p65 acetylation.
|
| In Vivo |
SRTCX1003 (3-100 mg/kg; oral; once) 在小鼠炎症模型中降低 LPS (HY-D1056) 刺激的 TNFα 和 IL-12p40 的产生[1]。 Animal Model: Male BALB/c mice, LPS-induced inflammation mouse model[1] Dosage: 3, 10, 30 and 100 mg/kg Administration: Oral, 60 minutes prior to LPS administration Result: Dose-dependently reduced LPS-stimulated TNFα and IL-12p40 production.
|
| References |
[1]. Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity.
|
